Navigation Links
Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program
Date:2/8/2008

Clinical Experts To Oversee Phase 3 Program of CGT-2168

MENLO PARK, Calif., Feb. 8 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc., today named a distinguished international panel of medical experts to serve on the Scientific Steering Committee charged with overseeing COGENT, the company's global Phase 3 clinical trial program for its novel combination antiplatelet product CGT-2168.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO)

The panel includes experts in the fields of cardiology, gastroenterology and clinical investigation. "We are extremely pleased that these accomplished clinical scientists will advise us on the COGENT program. Their participation will help ensure its scientific success," said Cogentus Chairman and Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D.

Members of the COGENT Scientific Steering Committee are:

-- Dr. Deepak Bhatt, Associate Director, Cardiovascular Coordinating

Center, Cleveland Clinic, Cleveland, Ohio

-- Dr. Marc Cohen, Director of the Division of Cardiology, Newark Beth

Israel Medical Center, Newark, New Jersey

-- Dr. Byron Cryer, John C. Vanatta III Professor of Medicine and

Associate Dean for Minority Affairs, Southwestern Medical School,

Dallas, Texas

-- Dr. Angel Lanas, Service of Gastroenterology, University Hospital,

Zaragoza, Spain

-- Dr. Thomas Schnitzer, Professor of Medicine, Division of Rheumatology,

Northwestern University Feinberg School of Medicine, Chicago, Illinois

The Scientific Steering Committee will be responsible for providing scientific and clinical oversight and advice to ensure the data that emerge from the COGENT program are of the highest quality and that the highest level of scientific conduct is maintained.

The ongoing COGENT program will evaluate the efficacy and safety of Cogentus's lead product, CGT-2168, which combines the antiplatelet medicine clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) and a gastroprotectant (omeprazole).

While antiplatelet therapy has been shown to be effective in preventing major cardiovascular events, it is associated with significant gastrointestinal side effects including bleeding, which can interrupt treatment, may require hospitalization or in some cases even result in death. Bleeding from the use of the antiplatelet drugs aspirin and clopidogrel has been shown respectively to be the third and fourth most common causes of U.S. emergency room visits by older adults experiencing adverse drug events.

"It is critical that patients are able to remain on treatment," Dr. Goldsmith said. A new analysis published in this week's Journal of the American Medical Association showed that patients with acute coronary syndrome who stopped taking Plavix nearly doubled their risk of heart attack or death within the first 90 days following the end of treatment.

CGT-2168 is designed to maintain full protective cardiovascular benefits while reducing the potentially serious gastrointestinal side effects commonly associated with antiplatelet therapy. Early results with CGT-2168 show excellent absorption and metabolism of clopidogrel that are unaffected by the delayed-release omeprazole within this combination product. Cogentus believes these findings suggest the novel formulation avoids a drug-drug interaction that has been reported when the individual marketed drugs are co-administered.

"It is important for patients to receive the full cardiovascular effect of dual antiplatelet therapy while reducing gastrointestinal side effects," said Steering Committee member Dr. Marc Cohen. "The COGENT program is evaluating whether CGT-2168 will maintain the cardiovascular benefits of treatment while minimizing bleeding."

"We believe CGT-2168 has the potential to offer an effective yet safer treatment option for the millions of patients who require antiplatelet therapy. With the help of the Scientific Steering Committee, we are committed to a thorough evaluation of the potentially significant benefits of this new medicine," Dr. Goldsmith said.

ABOUT COGENT

COGENT stands for the Clopidogrel and the Optimization of Gastrointestinal Events Trial. The program is expected to enroll more than 4,000 patients at hundreds of sites in the United States, Canada, Europe and South America. The COGENT program is designed to measure the incidence of upper gastrointestinal bleeding and ulcers in patients who take CGT-2168 and aspirin compared with patients who take clopidogrel and aspirin. The vast majority of patients who take clopidogrel also take aspirin.

Physicians and patients interested in obtaining more information about COGENT should go to http://www.clinicaltrials.gov.

ABOUT COGENTUS

Cogentus Pharmaceuticals, Inc., of Menlo Park, CA, is a privately held specialty pharmaceutical company founded in 2006. Cogentus (http://www.cogentus.net) is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.

Plavix(R) is a registered trademark of Sanofi-Aventis.


'/>"/>
SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cogentus Pharmaceuticals Completes $62.5 Million Private Financing
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: